Business
Zura Bio Announces Chief Financial Officer Transition
HENDERSON, Nev., July 01, 2025--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transitio
About this update from Zura Bio Limited
[{"type":"image","alt":"Eric Hyllengren","displaySize":"","headline":null,"caption":"Eric Hyllengren","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":358,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/1c452a587d12da0893ec245694dc8aed"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zSZQSQoP52iBovr0jdSWYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTk0NTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/1c452a587d12da0893ec245694dc8aed","width":358,"height":480}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/245bdb385ef9108e201544263053e995"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/WNz5.6WwgZPDDbkA1eicIQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/245bdb385ef9108e201544263053e995","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/tZSv2VFeClw7BrN6laCgPQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/245bdb385ef9108e201544263053e995","width":1024,"height":512}}},{"type":"text","content":"HENDERSON, Nev., July 01, 2025--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA) ("Zura Bio"), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transition.","length":529,"tagName":"p"},{"type":"text","content":"Mr. Badial joined Zura Bio in March 2023, at the time of its business combination with JATT Acquisition Corporation. He led the development of Zura Bio’s internal financial and operational systems, contributed to shaping its financial strategy, and participated in capital-raising efforts that supported the company’s early growth.","length":331,"tagName":"p"},{"type":"text","content":"Mr. Hyllengren brings over 20 years of financial leadership experience in the life sciences and biotechnology sectors. He most rece...